COVID-19 infection creates immunity for at least six months: study

Individuals infected with coronavirus are unlikely to catch the illness again for at least six months, researchers at the University of Oxford said Friday. The finding comes as part of a large-scale study into Covid-19 reinfection after observations from healthcare professionals that the phenomenon was relatively rare. ....read more

Prevention of Antimicrobial Resistance in the Covid-19

Antimicrobial resistance (AMR) is a global concern and hampers treatment of common infections. It needs to be addressed urgently especially when we are in the midst of a pandemic. Join us today on Medtalks with Dr K K Aggarwal COVID edition at 7:00 pm for a discussion on how antimicrobial resistance can be prevented in the Covid-19 era.Just click on www.facebook.com/drkkaggarwal or https://perfecthealthmela.com/vevent2/hall1a.php

CMAAO Coronavirus Facts and Myth Buster: mRNA vaccine; Mental health

With input from Dr Monica Vasudev 1151: Early analysis shows 94.5% efficacy for mRNA-1273 vaccine against SARS-CoV-2DG Alert excerpts:1.An interim review of results from the Phase III COVEtrial revealed that mRNA-1273, an experimental messenger RNA vaccine encoding the stabilized prefusion SARS-CoV-2 spike protein, is safe and effective for prevention of symptomatic COVID-19 in adults. 2.The US National Institute of Allergy and Infectious Diseases (NIAID) is co-developing the vaccine candidate. It stated that the vaccine has a statistically significant efficacy rate of 94.5% on the basis of an initial analysis of 95 cases with symptomatic COVID-19. ....read more

World COVID Meter 21st November: Acute manageable immunogenic thrombogenic inflammatory viral disease pandemic

Cases: 1M April 2, 2M April 15, 3M April 27, 4M May 8, 5M May 20, 6M May 30, 7M June 7, 8M June 15, 9M June 22, 10M June 29th, 11M July 4, 12M July 8, 13M July 13, 14M July 17, 15M July 23, 16M July 25, 17M July 29, 18M August 1, 19M August 6, 20M August 10, 21M August 16, 22M August 19, 23M August 21, 24M August 27, 25M August 30, 26M September 3, 27M September 7, 28M September 10, 29M September 14, 30M September 18, 31M September 21, 32M September 23, 33M September 28, 34M October 1, 35M October 4, 36M October 8, 37M October 11, 38M October 14, 39M October 17, 40M October 19, 41M October 22, 42M October 24, 43M October 26, 44M October 28, 45M October 30, 46M November 2, 47M November 4, 48M November 6, 49M November 7, 50M November 8, 51M November 10, 52M November 12, 53M November 14, 54M November 15, 55M November 17, 56M November 19 Ground Zero: Wuhan - in live animal market or cafeteria for animal pathogens: 10th January; Total cases are based on RT PCR, 67% sensitivity Coronavirus Cases: 57,902,489,Deaths: 1,377,539,Recovered: 40,103,358,ACTIVE CASES 16,421,592 ....read more

eSpiritual: Sattchittaananda: The soul characteristics (Absolute Existence -Absolute Knowledge)

Satt means ‘truth or knowingness’Chitta means ‘consciousness-based’Ananda means ‘bliss or inner happiness’The soul, in Vedic description, is described as Sattchittaananda. People in touch with their soul speak the truth, take consciousness-based decisions and experience inner happiness. ....read more

Video of The day

Vaccine update and Treatment difficulties

Healthcare News Monitor

Parliamentary panel on COVID-19: Pvt hospitals charged exorbitant fees; spending on health abysmally low

livemint

New Delhi: Amid rising COVID-19 cases, inadequate beds in government hospitals and absence of specific guidelines for COVID treatment resulted in private hospitals charging exorbitant fees, a parliamentary panel on Saturday said, asserting that a sustainable pricing model could have averted many deaths. Chairperson of the parliamentary standing committee on health Ram Gopal Yadav submitted the report on Outbreak of Pandemic Covid-19 and its Management, to Rajya Sabha Chairman M Venkaiah Naidu.

Indian co had adverse event during vaccine trial; experts push for transparency

health.economictimes

Mumbai: Hyderabad-based Bharat Biotech’s potential Covid-19 vaccine reported a serious adverse event during clinical trials in August, even as it has now initiated Phase III. The adverse event occurred in a 35-year old participant with no comorbidities, who was part of Phase 1 trials in August, investigators monitoring the study confirmed to TOI on condition of anonymity. The company also tweaked its trial protocol for Phase II, with the dosing regimen modified from 14 days to 28 days, and the number of participants nearly halved to 380 from the earlier 750, sources added. Bharat Biotech, in collaboration with apex research body Indian Council of Medical Research (ICMR), has developed Covaxin, an inactivated virus vaccine, for which it commenced Phase III clinical trials on November 16, involving around 26,000 participants. The adverse event did not lead to any life-threatening reaction, and hence, was categorised as “not severe and related to the vaccine”, they added.

AstraZeneca begins trials on antibody cocktail to prevent COVID-19

expresspharma.in

AstraZeneca started late-stage trials of an experimental long-acting monoclonal antibody combination drug it hopes could be used as a so-called prophylactic to prevent COVID-19 infection in at-risk people for up to 12 months. The Phase III international clinical trial will recruit a total of 5,000 people across countries in Europe and the US to assess the safety and effectiveness of the antibody cocktail, known as AZD7442. The prophylactic treatment differs from a vaccine in that it introduces antibodies, rather than prompting the body’s immune system to make them. It may prove useful in people whose immune systems are weaker or compromised, and who don’t respond to vaccination. Separately, AstraZeneca is developing a COVID-19 vaccine in conjunction with researchers at Oxford University.

Regeneron gets emergency US clearance for Covid-19 therapy

The Indian Express

Regeneron Pharmaceuticals Inc.’s antibody cocktail received an emergency use authorization from U.S. drug regulators for treatment of early Covid-19 symptoms, adding to the expanding arsenal of therapies available to physicians. The treatment, administered to President Donald Trump after he contracted the coronavirus in October, consists of two monoclonal antibodies that target the spike protein used by the virus to enter cells. Trump was treated with the drug based on a compassionate-use request by his doctors.